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From Hospital to Drugstore: Insurance and the Shift to Outpatient Care
Abstract
As policymakers consider whether and how to add prescription drug coverage to Medicare, they need to
understand the relationship between insurance coverage and the adoption of new medical technologies,
including drugs. Even the direction of these relationships is not always so clear. In this Issue Brief, Drs.
Danzon and Pauly examine the shift from inpatient to outpatient care in the last 20 years, and ask two
broad questions: to what extent was this shift encouraged by changes in insurance, and to what extent
was insurance coverage influenced by this shift?

License
This work is licensed under a Creative Commons Attribution-No Derivative Works 4.0 License.

This brief is available at ScholarlyCommons: https://repository.upenn.edu/ldi_issuebriefs/24

LDI Issue Brief
Volume 7, Number 2
October 2001

Patricia M. Danzon, PhD
LDI Senior Fellow,
Celia Moh Professor of
Health Care Systems
University of Pennsylvania
Mark V. Pauly, PhD
LDI Senior Fellow,
Bendheim Professor of
Health Care Systems
University of Pennsylvania

Shift to outpatient care is
matched by shift in
insurance coverage

Leonard Davis Institute of Health Economics

From Hospital to Drugstore: Insurance and the
Shift to Outpatient Care
Editor’s Note: As policymakers consider whether and how to add prescription drug
coverage to Medicare, they need to understand the relationship between insurance
coverage and the adoption of new medical technologies, including drugs. Even the
direction of these relationships is not always so clear. In this Issue Brief, Drs. Danzon
and Pauly examine the shift from inpatient to outpatient care in the last 20 years,
and ask two broad questions: to what extent was this shift encouraged by changes in
insurance, and to what extent was insurance coverage influenced by this shift?

Beginning in the 1980s, the U.S. health care shifted from the inpatient to the
outpatient setting. Technological improvements resulted in more effective
outpatient drugs and procedures, leading to fewer hospitalizations and shorter
inpatient stays.
• From 1980-1998, the share of health spending attributed to hospital care
dropped from 42% to 33%. Meanwhile, outpatient care (as represented by
physician and drug spending) rose from 23% to 28% of all health spending.
• Drug spending (as a share of total health spending) rose from 5% in 1980 to 8%
in 1998. Drug insurance coverage grew at an even faster rate. The proportion of
all drug expenses paid out-of-pocket decreased from 66% in 1980 to 27% in
1998. Thus, in 1980 patients paid an average of $3.30 out of pocket for
pharmaceuticals per $100 spent on health care; in 1998 they paid $2.16.
• In this period, technological breakthroughs expanded the range of diseases that
could be treated by drug therapies, creating new classes of costly but effective
antidepressants, cholesterol-lowering medications, and antacids. These breakthroughs probably increased the demand for drug insurance. Conversely, insurance
coverage almost certainly stimulated the use of existing drugs, and may have
permitted the market to accommodate more costly but beneficial technologies.

Drug coverage in private
sector expands

To better understand how insurance for drugs changed, Danzon and Pauly used data
from the 1987 National Medical Expenditure Survey (NMES) and the 1996
Medical Expenditure Panel Survey (MEPS). They examined data for people under
age 65 who did not have public insurance, because this population is most likely to
buy stand-alone private insurance.

• In this population, the proportion of people with prescription drug expenses rose
from 56% in 1987 to 65% in 1996. In contrast, the proportion of the people
with inpatient expenses actually fell in the same time period.
• The proportion of people receiving drug insurance benefits rose from 28% to
65% However, there was no change in the proportion of the bill paid by
insurance for people who had some drug spending and also had drug coverage
(65% in 1987 vs. 64% in 1996).
• The authors conclude that insurance for drugs improved over this period, but the
change was not in the depth of coverage (percentage of expenses paid) for people
with existing drug benefits; rather, it was in the proportion of people who had
new drug coverage and used it.

Moral hazard: insurance
coverage contributes to
higher drug spending

The theory of “moral hazard” from insurance states that people use more services
when insurance, or some other third party, is paying. The authors sought to quantify
the extent to which drug insurance coverage contributed to the actual growth in
drug spending.
• Actual drug spending per person (adjusted for inflation) grew about 90% from
1987 to 1996. Some of those increases probably reflect the development and
adoption of new and more effective drugs, but some probably reflect more
generous insurance coverage for drugs.
• Previous estimates indicate that a 10% drop in the average out-of-pocket price of
drugs to consumers can lead to a 3%-5% increase in the quantity of drugs
purchased. From 1987 to 1996, the “average user price” (or out-of-pocket costs)
as a proportion of the total price of drugs dropped by more than 50%. Had this
decline not occurred, the authors estimate that the quantity of drugs purchased
would have been 15%-25% lower than it actually was.
• This calculation is probably an underestimate, the authors note, because it does
not take into account other ways that drug coverage could influence the demand
for drugs. For example, increased coverage might affect the availability of new
drugs, or it could prompt pharmaceutical companies to increase their advertising,
both to physicians and directly to consumers. The adoption of managed drug
benefits also reduced the time and hassle costs for consumers, who now simply
present a card at the pharmacy and pay their co-payment, rather than paying in
full and then seeking reimbursement from their insurers.

Improvements in outpatient
procedures and drugs makes
coverage more attractive

Through the 1960s, insurance coverage of outpatient drugs and physician services
was rare and incomplete, because these expenses were small and predictable. As
technological change produced more effective (but more costly) outpatient drugs
and procedures, insurance coverage of these expenses became more attractive to
consumers. Danzon and Pauly again used 1987 NMES and 1996 MEPS data to
illustrate this phenomenon in people under 65 who did not have public insurance.
• Between 1987 and 1996, outpatient expenses increased more rapidly than other
kinds of spending. In that time period, inpatient spending (in inflation-adjusted
dollars) decreased by 14% (per capita), while outpatient expenses increased 68%,
and drug spending rose 194%.

• Outpatient expenses shifted toward persons who already had high expenses in
other categories of health spending. Drug expenses, in particular, grew most
rapidly for the sickest people with the highest total spending. These shifts clearly
created incentives for consumers to purchase outpatient drug coverage.
• This suggests that growth in insurance coverage for drugs was itself stimulated by
growth in the range and effectiveness of drugs available, which raised the typical
individual’s expected drug expenses

Insurance markets respond
with new products
integrating inpatient and
outpatient care

In response to the growth of effective outpatient drugs and services, the private
sector developed new insurance products (especially managed care plans) and new
insurance technologies to control the costs of drugs (pharmacy benefit
management).
• Managed care offered coverage that integrated inpatient, outpatient and drug
coverage. This integration allowed them to take advantage of opportunities to
encourage more efficient forms of care regardless of whether that was provided
through inpatient services or pharmaceuticals.
• Pharmacy benefits managers (PBMs) developed strategies to handle multiple
small claims and control costs. These strategies include negotiating price
discounts from manufacturers, using formularies of preferred drugs, drug
utilization review, and mail-orders for chronic medications. PBMs turned to
card-based systems, where the pharmacy bills the plan electronically, to reduce the
time and hassle cost to the patient.
• The authors suggest that the development of managed care strategies to control
drug utilization may have been a necessary ingredient for this coverage to become
a cost-effective form of insurance.

POLICY IMPLICATIONS

This analysis suggests that the cause and effect relationships between costly but
beneficial pharmaceutical innovation, and the insurance coverage for that
innovation, are complex and bi-directional. Technology prompted insurance
coverage, and new insurance coverage raised costs (and probably stimulated new
technology as well). These complex arrangements relied partly on the benefits of
newly developed drugs, and partly on the creation of new insurance systems that
integrated the financial and clinical exposures insurers faced across historically
separate areas of care.
• The historical practice of developing coverage on a service-by-service basis
prevents efficiencies realized from shifting care from one kind of service (e.g.,
inpatient care) to another (e.g., outpatient drugs). Insurance that protects
consumers against financial loss should make payments based on a person’s total
medical care spending, rather than on the size of the components of that
spending.
• The private sector, overall, has responded well to shifts in care by designing new
insurance products. In failing to provide outpatient pharmaceutical coverage,
Medicare has lagged behind this trend. Many Medicare recipients have no drug
coverage, and many others obtain Medigap coverage for drugs, which provides
only limited protection.
Continued on back.

POLICY IMPLICATIONS
Continued

• The organizational separation of insurance coverage into inpatient and outpatient
care (and especially into drug and nondrug coverage) is undesirable. The harm
from having one insurer cover inpatient care and another cover drugs is likely to
be especially acute for Medicare.
• However a Medicare drug benefit is organized, policymakers should consider the
use of managed care techniques (such as PBMs) to improve the cost-effectiveness
of the coverage.
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